Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Oct 18 - Oct 23
On top of that, other menopause symptoms, including poor sleep and mood changes, can leave you craving sugary, comfort foods
Clinical eligibility is defined by a diagnosis of obesity, diabetes or overweight with other present risk factors
The most recent study from France titled GLP-1 receptor agonists and the risk of thyroid cancer (2) concluded that there was, in fact, an increased risk of all thyroid cancer and medullary thyroid cancer with the use of GLP-1 receptor agonists, in particular after 1-3 years of treatment
Bakirci, S., Dabague, J., Eder, L., McGonagle, D
Putting the trial numbers into perspective Historically, anti-obesity drugs produced average weight losses in the single digits (510%), and even the best options rarely approached double-digit percentages at the population level
Clinical trials and results Retatrutide is currently in phase 3 clinical trials for weight loss, but results from phase 2 trials are promising
